NCI Navigant Consulting Inc.

Navigant Expands Presence in Berlin

Navigant (NYSE: NCI) announced today the expansion of its life sciences practice to Berlin, Germany, creating a beachhead to serve continental Europe. The office will offer the full suite of capabilities of Navigant’s life sciences practice to optimize decision-making at the product, business unit, and enterprise level. These solutions include product planning and development, market access, pricing and reimbursement, commercialization, franchise and business strategy, regulatory and compliance capabilities, and corporate strategy. The practice will be co-located with Ecofys, a Navigant company.

Navigant has built an international reputation as a preferred expert and trusted partner for life sciences companies seeking to mitigate their risks while achieving exceptional growth. Its life sciences consulting team provides services to pharmaceutical, specialty, and medical technology organizations facing strategic, operational, dispute, compliance, and investigative issues.

“Navigant continues to invest in continental Europe to better support our local clients and to continue to attract the very best talent to support life sciences’ commercial, market access, and medical technology consulting services,” said Eduardo Schur, global practice area leader of life sciences. “This new office builds on our extensive presence in London. Europe is a hub for innovation and progressive policy in the life sciences industry, and we look forward to working side by side with our clients across the continent.”

The expansion adds to Navigant’s geographic growth strategy for life sciences. In recent months, Navigant acquired substantially all of the assets of Quorum Consulting, Inc., a San Francisco-based life sciences consulting firm that helps develop clinical evidence and outcomes data to support payer coverage policies and product adoption.

Navigant’s Healthcare segment is composed of consultants, former provider administrators, clinicians, and other experts with decades of strategy, operational/clinical consulting, managed services, revenue cycle management, and outsourcing experience. Professionals collaborate with hospitals and health systems, physician enterprises, payers, government, and life sciences entities, providing strategic, performance improvement, and business process management solutions that help them meet quality and financial goals.

About Navigant

Navigant Consulting, Inc. (NYSE: NCI) is a specialized, global professional services firm that helps clients take control of their future. Navigant’s professionals apply deep industry knowledge, substantive technical expertise, and an enterprising approach to help clients build, manage, and/or protect their business interests. With a focus on markets and clients facing transformational change and significant regulatory or legal pressures, the firm primarily serves clients in the healthcare, energy, and financial services industries. Across a range of advisory, consulting, outsourcing, and technology/analytics services, Navigant’s practitioners bring sharp insight that pinpoints opportunities and delivers powerful results. More information about Navigant can be found at navigant.com.

EN
29/01/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Navigant Consulting Inc.

NAVIGANT CNSL.INCO. is slightly downgraded to Slightly Positive due to...

The independent financial analyst theScreener just slightly lowered the general evaluation of NAVIGANT CNSL.INCO. (US), active in the Business Support Services industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains unchanged and can be qualified as defensive. However, a marginally less favourable environment forces theScreener to downgrade slightly the title, which now shows an overall rating of Slightly Positive. As o...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2019 04 17

BZH currently trades near recent lows relative to UAFRS-based (Uniform) Earnings, with a 6.7x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to decline from 11% in 2018 to 5% in 2023, accompanied by 1% Uniform Asset growth going forward. However, analysts have bullish expectations, projecting Uniform ROA to expand to 13% through 2020, accompanied by 3% Uniform Asset shrinkage. Moreover, management is confident in structural plan options, their balanced growth...

Valens Research
  • Valens Research

NCI - Embedded Expectations Analysis - 2019 04 11

Navigant Consulting Inc. (NCI:USA) currently trades below recent averages relative to UAFRS-based (Uniform) Earnings, with a 15.6x Uniform P/E. Even at these levels, the market is pricing in expectations for Uniform ROA to improve from a low of 9% in 2018 to 11% in 2023. Specifically, markets appear optimistic about the competitive position of the firm's remaining industry segments and the potential to drive top-line growth. However, they may be skeptical of the benefits of a simplified portfol...

MarketLine Department
  • MarketLine Department

ICF International, Inc. - Mergers & Acquisitions (M&A), Partnerships &...

Summary Marketline's ICF International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by ICF International, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of th...

2 directors sold after exercising options/sold

Two Directors at Navigant Consulting Inc sold after exercising options/sold 49,598 shares at between 24.120USD and 24.240USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch